Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Search
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Moldova
Moldova
Albania
Albania
Uzbekistan
Uzbekistan
Fredrik Gruenenfelder
, Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Social health and wellbeing
Social health and wellbeing
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Sant Cugat del Vallès
The site in Sant Cugat del Vallès focuses on pharmaceutical production and is one of the production sites of the RESPIMAT®.
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Digital Therapeutic
Digital Therapeutic
Slovenia
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Serbia
Serbia
Latvia
Latvia
Lithuania
Lithuania
Bulgaria
Bulgaria